A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Hookworm (Ancylostoma Duodenale and Necator Americanus), Ascaris Lumbricoides, and Trichuris Trichiura in Pediatric and Adult Participants
Latest Information Update: 26 Jul 2024
At a glance
- Drugs ZP5 9676 (Primary)
- Indications Helminthiasis
- Focus Registrational; Therapeutic Use
- Sponsors Zero Point Five Therapeutics
- 23 Jul 2024 Planned initiation date changed from 1 Apr 2024 to 1 Oct 2024.
- 16 Nov 2023 New trial record